Q1 n (%) | Q4 n (%) | Q1/Q4 | ||
---|---|---|---|---|

RR* | 95% CI | |||

LVIDd | ||||

Mortality | 153 (13.2) | 351 (27.3) | 0.442 | 0.365–0.534 |

M + M | 245 (21.1) | 501 (39.0) | 0.485 | 0.416–0.565 |

EF | ||||

Mortality | 202 (13.9) | 325 (26.4) | 0.501 | 0.420–0.597 |

M + M | 329 (22.6) | 495 (40.2) | 0.506 | 0.440–0.582 |

LVIDd + EF | ||||

Mortality | 55 (10.7) | 155 (30.6) | 0.319 | 0.234–0.434 |

M + M | 87 (16.9) | 227 (44.9) | 0.323 | 0.253–0.414 |

CI = confidence interval; EF = ejection fraction; LVIDd = left ventricular internal diastolic diameter; M + M = combined mortality and morbidity; n = number of patients with baseline left ventricular measurements who had an event; Q = quartile; RR = risk ratios by Cox regression.

↵* p < 0.0001. LVIDd, EF, and combined quartiles at baseline are compared with outcomes (mortality and M + M) from pooled valsartan and placebo data, using univariate Cox proportional hazards analysis.